JP2012511586A5 - - Google Patents

Download PDF

Info

Publication number
JP2012511586A5
JP2012511586A5 JP2011540882A JP2011540882A JP2012511586A5 JP 2012511586 A5 JP2012511586 A5 JP 2012511586A5 JP 2011540882 A JP2011540882 A JP 2011540882A JP 2011540882 A JP2011540882 A JP 2011540882A JP 2012511586 A5 JP2012511586 A5 JP 2012511586A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
glp
human
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011540882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012511586A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/067469 external-priority patent/WO2010068735A1/en
Publication of JP2012511586A publication Critical patent/JP2012511586A/ja
Publication of JP2012511586A5 publication Critical patent/JP2012511586A5/ja
Pending legal-status Critical Current

Links

JP2011540882A 2008-12-10 2009-12-10 医薬組成物 Pending JP2012511586A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12122908P 2008-12-10 2008-12-10
US61/121,229 2008-12-10
US15090909P 2009-02-09 2009-02-09
US61/150,909 2009-02-09
US16399509P 2009-03-27 2009-03-27
US61/163,995 2009-03-27
US23872309P 2009-09-01 2009-09-01
US61/238,723 2009-09-01
PCT/US2009/067469 WO2010068735A1 (en) 2008-12-10 2009-12-10 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2012511586A JP2012511586A (ja) 2012-05-24
JP2012511586A5 true JP2012511586A5 (https=) 2013-01-31

Family

ID=42243062

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540882A Pending JP2012511586A (ja) 2008-12-10 2009-12-10 医薬組成物

Country Status (14)

Country Link
US (3) US8748377B2 (https=)
EP (1) EP2373681B1 (https=)
JP (1) JP2012511586A (https=)
CY (1) CY1118731T1 (https=)
DK (1) DK2373681T3 (https=)
ES (1) ES2620610T3 (https=)
HR (1) HRP20170478T1 (https=)
HU (1) HUE031900T2 (https=)
LT (1) LT2373681T (https=)
PL (1) PL2373681T3 (https=)
PT (1) PT2373681T (https=)
SI (1) SI2373681T1 (https=)
SM (1) SMT201700189T1 (https=)
WO (1) WO2010068735A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2373681T (pt) 2008-12-10 2017-04-11 Glaxosmithkline Llc Composições farmacêuticas de albiglutida
US8691763B2 (en) 2010-05-04 2014-04-08 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
EP2866825B1 (en) 2012-07-01 2020-04-08 Novo Nordisk A/S Use of long-acting glp-1 peptides
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
SI3004155T1 (sl) 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptidna spojina
US20140378374A1 (en) * 2013-06-21 2014-12-25 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treatment
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TW201613630A (en) * 2014-06-25 2016-04-16 Glaxosmithkline Llc Pharmaceutical compositions
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
JP6995042B2 (ja) 2016-05-24 2022-02-04 武田薬品工業株式会社 ペプチド化合物
EP3684793A1 (en) 2017-09-22 2020-07-29 Regeneron Pharmaceuticals, Inc. Glucagon-like peptide 1 receptor agonists and uses thereof
CA3078652A1 (en) 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
CN103356996A (zh) 2000-05-19 2013-10-23 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
NZ519752A (en) 2000-10-20 2005-04-29 Amylin Pharmaceuticals Inc Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
AU3938402A (en) 2000-12-13 2002-06-24 Lilly Co Eli Chronic treatment regimen using glucagon-like insulinotropic peptides
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
KR20040054729A (ko) 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003200839B2 (en) 2002-01-08 2008-12-11 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
WO2003084563A1 (en) 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
EP1610811A4 (en) 2002-12-17 2008-03-26 Amylin Pharmaceuticals Inc PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US20070128193A1 (en) 2004-12-22 2007-06-07 O'neil Karyn T GLP-1 agonists, compositions, methods and uses
CA2599594A1 (en) 2004-12-24 2006-07-13 Amylin Pharmaceuticals, Inc. Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
CN102343084A (zh) 2005-03-31 2012-02-08 安米林药品公司 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
US20080200383A1 (en) * 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
DK1888103T3 (da) 2005-04-11 2012-04-23 Amylin Pharmaceuticals Inc Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
US8202837B2 (en) * 2005-11-04 2012-06-19 Glaxosmithkline Llc Methods for administering hypoglycemic agents
WO2007139941A2 (en) 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
WO2008011446A2 (en) 2006-07-18 2008-01-24 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
WO2008019143A2 (en) 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc Use of exendins and glp-i receptor agonists for altering lipoprotein particle size and subclass composition
TWI430806B (zh) * 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法
EP2163243A1 (en) 2008-09-12 2010-03-17 Biocompatibles UK Limited Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
PT2373681T (pt) 2008-12-10 2017-04-11 Glaxosmithkline Llc Composições farmacêuticas de albiglutida

Similar Documents

Publication Publication Date Title
JP2012511586A5 (https=)
Kumar et al. Therapeutic molecules against type 2 diabetes: What we have and what are we expecting?
HRP20170478T1 (hr) Farmaceutski pripravci albiglutida
Cvetković et al. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea)
Choe et al. Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists
EP2324853B1 (en) Lixisenatide as add-on to metformin in the treatment of diabetes type 2
JP2016128483A (ja) 代謝症候群を処置するための医薬組成物
WO2014177623A1 (en) Novel administration regime
US8003605B2 (en) Minimising body weight gain in insulin treatment
WO2008071010A1 (en) Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
Sisson Liraglutide: clinical pharmacology and considerations for therapy
US20250319163A1 (en) Treatment of type 2 diabetes mellitus
JP2024150496A (ja) インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
EP1971363A1 (en) Combination treatments with gastrin agonists for diabetes and related diseases
Gallwitz Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass
Chia et al. Role and development of GLP-1 receptor agonists in the management of diabetes
Edwards GLP-1: target for a new class of antidiabetic agents?
Pitocco et al. Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents
Groves et al. Standard and novel treatment options for metabolic syndrome and diabetes mellitus
Imam Diabetes: a new horizon and approach to management
Klonoff Incretin therapy for type 2 diabetes mellitus
Thongtang et al. Incretins: the novel therapy of type 2 diabetes
Trujillo Incretin hormones in the treatment of type 2 diabetes
McCall Combination therapy for treatment of type 2 diabetes
Vilsbøll et al. Glucagon-like peptide-1 and diabetes treatment